TNFRSF9 and inflammatory bowel disease: Nevertheless, our findings in the DSS colitis model suggest that neutralizing CD137 with antagonistic anti-CD137 antibodies would not be beneficial for the treatment DSS-induced colitis and possibly also not for IBD patients.